Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients

Transplantation

Volumn 86, Issue 2, 2008, Pages 245-250

  Celik, Sultan ^a   Doesch, Andreas ^a   Erbel, Christian ^a   Blessing, Erwin ^a   Ammon, Kerstin ^a   Koch, Achim ^a   Katus, Hugo A ^a   Dengler, Thomas J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Heart transplantation; Hypertriglyceridemia; Omega 3 fatty acids; Sirolimus or everolimus

Indexed keywords

ANTICOAGULANT AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EVEROLIMUS; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEGA 3 FATTY ACID; PRAVASTATIN; RAPAMYCIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZODIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ABNORMAL LABORATORY RESULT; ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAFT RECIPIENT; HEART GRAFT; HEART PROTECTION; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; MALE; NAUSEA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SIDE EFFECT; STROKE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; AGED; HEART FAILURE; METABOLISM; METHODOLOGY; MIDDLE AGED; TIME;

AGED; FATTY ACIDS, OMEGA-3; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 49249112376     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318177281e     Document Type: Article

References (51)

1. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138(5 Pt 2): S419.
2. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation1997; 63: 331.
3. Ballantyne CM, el Masri B, Morrisett JD, et al. Pathophysiology and treatment of lipid perturbation after cardiac transplantation. Curr Opin Cardiol 1997; 12: 153.
4. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation1999; 68: 708.
5. Meiser BM, Uberfuhr P, Fuchs A, et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant 1998; 17: 782.
6. Meiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: Importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999; 18: 143.
7. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
8. Meiser BM, Groetzner J, Kaczmarek I, et al. Tacrolimus or cyclospor-ine: Which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation2004; 78: 591.
9. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
10. Mukherjee T, Shah BV. Sirolimus: A new immunosuppressant. J Assoc Physicians India 2005; 53: 885.
11. Sehgal SN. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35(3 suppl): 7S.
12. Shitrit D, Yussim A, Kramer MR. Role of siroliumus, a novel immuno-suppressive drug in heart and lung transplantation. Respir Med 2004; 98: 892.
13. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002; 11: 1845.
14. Olyaei AJ, Demattos AM, Bennett WM. Nephrotoxicity of immuno-suppressive drugs: New insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384.
15. Oberbauer R, Kreis H, Johnson RW, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation2003; 76: 364.
16. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leuko-penia in renal transplant recipients: Risk factors, incidence, progression, and management. Transplantation2000; 69: 2085.
17. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486.
18. O'Rourke B, Barbir M, Mitchell AG, et al. Efficacy and safety of fluva-statin therapy for hypercholesterolemia after heart transplantation: Results of a randomised double blind placebo controlled study. Int J Cardiol 2004; 94: 235.
19. Boissonnat P, Salen P, Guidollet J, et al. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation1994; 58: 245.
20. Roeders N, Knoop C, Antoine M, et al. Fibrate-induced increase in blood urea and creatinine: Is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000; 15: 1993.
21. Stone NJ. Fish consumption, fish oil, lipids, and coronary heart disease [review]. Am J Clin Nutr 1997; 65: 1083.
22. Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279: 23.
23. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002; 346: 1113.
24. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354: 447. Kindly note that Refs. 24 and 52, and Refs.36 and 46 are identical, therefore Refs. 46 and 52 have been deleted and references are renumbered in both the text and the list. Please check.
25. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysisofthe results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897.
26. Bucher HC, Hengstler P, Schindler C, et al. N-3 polyunsaturated fatty acids in coronary heart disease: A meta-αnalysis of randomized controlled trials. Am J Med 2002; 112: 298.
27. Harris WS. N-3 Long-chain polyunsaturated fatty acids reduce risk of coronary heart disease death: Extending the evidence to the elderly. Am J Clin Nutr 2003; 77: 279.
28. Marsden JR. Effectofdietary fish oilon hyperlipidaemia dueto isotreti-noin and etretinate. Hum Toxicol 1987; 6: 219.
29. Kendrach MG, Kelly-Freeman M. Approximate equivalent revostatin doses for temporary statin interchange programs. Ann Pharmacother 2004; 38: 1286.
30. Grace KA, Swiecki J, Hyatt R, et al. Implemantation of a therapeutic interchange clinic for HMG-CoA reductase inhibitors.Am J Health Syst Pharm 2002; 59: 1077.
31. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582.
32. Winter GL, Marboe CC, Billingham ME. The international society for heart and lung transplantation grading system for heart transplant biopsy specimens: Carification and commentary. J Heart Lung Transplant 1998; 17: 754.
33. StewartS,Winters GL, Fishbein MC,etal. Revisionofthe 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710.
34. Ballantyne CM, Radovancevic B, Farmer JA, etal. Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992; 19: 1315.
35. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301.
36. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383.
37. CollinsR, ArmitageJ, Parish S,etal. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005.
38. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
39. Dr. H. Lehn. Novartis trial A2411, 12 month results, personal communication, Berlin, Germany.
40. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: Implications for atherosclerosis and transplantation-αssociated atherosclerosis. Circ Res 2002; 90: 703.
41. Gumprecht J, Zychma M, Grzeszczak W, et al. Simvastatin-induced rhabdomyolysis in a CsA-treated renal transplant recipient. Med Sci Monit 2003; 9: CS89.
42. East C, Alivizatos PA, Grundy SM, et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318: 47.
43. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety. Eur Heart J 1995; 16: 5.
44. Bermingham RP, Whitsitt TB, Smart ML, et al. Rhabdomyolysis in a patient receiving the combinationofcerivastatin and gemfibrozil. Am J Health Syst Pharm 2000; 57: 461.
45. Pogson GW, Kindred LH, Carper B. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol 1999; 83: 1146.
46. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Survival Study (4S). Lancet 1995; 345: 1274.
47. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996; 335: 1001.
48. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
49. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003; 107: 93.
50. Nordøy A, Bønaa KH, Nilsen H, et al. Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med 1998; 243: 163.
51. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapenta-enoic acid onmajor coronary eventsinhypercholesterolaemic patients. Lancet 2007; 369: 1090.